LETERMOVIR (letermovir) by Merck & Co. is dna terminase complex inhibitors [moa]. Approved for cytomegalovirus dna terminase complex inhibitor [epc].
Drug data last refreshed 1mo ago
DNA Terminase Complex Inhibitors
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)
Pharmacokinetics of Oral Letermovir in Adults With End-Stage Kidney Disease With or Without Haemodialysis
A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus
Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients
Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients
Worked on LETERMOVIR at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.